Managing Insomnia in the Primary Care Setting: Moving Towards Safer Therapies

Released On
January 9, 2020

Expires On
January 9, 2021

Media Type
Internet

Completion Time
60 minutes

Specialty
Primary Care Providers: Physicians, Physicians Assistants and Nurse Practitioners

Topic(s)
Sleep Medicine

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Boston University School of Medicine, Postgraduate Institute for Medicine, and Rockpointe.

 

Supported by an independent educational grant from Eisai.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Physicians — maximum of 1.0 ABIM MOC points
  • Physicians — maximum of 1.0 MIPS credits
  • Physicians — maximum of 1.0 AAFP Prescribed Credits
  • Nurses — 1.0 contact hours, 0.5 pharmacotherapy credit for APRNs.
  • Physicians Assistants — maximum of 1.0 AAPA Category CME credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for primary care providers, including physicians, physician assistants, nurse practitioners, and relevant sub-specialty clinicians, who are on the frontlines of recognizing and diagnosing adults with insomnia.

Program Overview

Insomnia is an underrecognized, undertreated, and, unfortunately, often mistreated condition, putting patients at serious health risks that are preventable with evidence-based care. For patients who do not adequately respond to cognitive behavioral therapy for insomnia, multiple pharmacologic options are available that can be tailored to specific insomnia symptoms, and newer agents have improved safety profiles over conventional hypnotics. It is vital that clinicians are able to differentiate these agents based on patient symptoms to make optimal treatment selections to meet the needs of each individual patient.

The educational program, Managing Insomnia in the Primary Care Setting: Moving Towards Safer Therapies, will reinforce the impact of insomnia on patient health, review related comorbidities, examine current and emerging therapies, and provide strategies for engaging patients in their insomnia management using a shared decision-making approach.

Learning Objectives

This program is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine.

At the conclusion of this activity, participants should be able to:

  • Identify the health risks and other factors associated with insomnia that indicate the need for timely and adequate assessment
  • Implement personalized treatment plans for patients with insomnia based on current evidence
  • Assess current clinical data on pharmacotherapies in development for insomnia
  • Develop strategies for shared decision-making with patients regarding the management of their insomnia

Steering Committee

Karl Doghramji, MD

Professor of Psychiatry, Neurology, and Medicine
Director, Jefferson Sleep Disorders Center
Sidney Kimmel Medical College of Thomas Jefferson University
Philadelphia, PA

Paul P. Doghramji, MD

Senior Family Physician
Collegeville Family Practice
Medical Director of Health Services
Ursinus College
Collegeville, PA

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Boston University School of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about the accreditation of this program, please email: cme@bu.edu.

ABIM MOC Designation Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through BUSM’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

MIPS Credit Designation

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).

American Academy of Family Physicians (AAFP) Credit

This Enduring Material activity, Managing Insomnia in the Primary Care Setting: Moving Towards Safer Therapies, has been reviewed and is acceptable for up to 1.00 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 1/9/2020. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Joint Provider Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Rockpointe Corporation. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Designated for 0.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Physician Assistant Credit Designation

Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 1/9/2021. PAs should only claim credit commensurate with the extent of their participation.

Disclosures of Conflicts of Interest

This educational activity has been produced in adherence with the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Faculty and Steering Committee Disclosures

The faculty and steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Karl Doghramji, MD: Consultant: Eisai, Merck, Pfizer; Stockholder: Merck

Paul P. Doghramji, MD: Advisory Board: Eisai, Jazz; Speaker's Bureau: Allergan

Sanford Auerbach, MD (BUSM Course Director): Nothing to disclose

Non-faculty Disclosures

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Chad Williamson, MS, MBA, CMPP; Blair St. Amand; Elizabeth Drury; Natalie Sanfratello, MPH; Brian Jack, MD; PIM Planners and Managers: Nothing to disclose

Instructions for Participation and Credit

There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive credit for participation, participants must complete the post-test (achieving a passing grade) and program evaluation. Certificates can be printed immediately.

Media

Internet

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclosure of Unlabeled Use

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer

THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.

The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

The opinions expressed in this educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.